GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)

Heartland Financial USA Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	37,397	37,492	34,537	32,517	32,780	29,256
Other Revenue	80.8	-	-	-	-	-
Revenue	37,478	37,492	34,537	32,517	32,780	29,256
Revenue Growth (YoY)	6.88%	8.56%	6.21%	-0.80%	12.05%	-9.27%
Cost of Revenue	14,063	14,139	13,552	13,041	13,782	12,824
Gross Profit	23,415	23,354	20,985	19,476	18,998	16,432
Selling, General & Admin	7,031	7,018	7,358	7,062	7,397	6,858
Other Operating Expenses	4,285	4,524	4,541	4,272	3,931	3,594
Operating Expenses	11,975	12,210	12,595	11,992	12,010	11,236
Operating Income	11,440	11,143	8,390	7,484	6,988	5,196
Interest Expense	-13.64	-13.14	-17.99	-18.12	-19.96	-35.31
Interest & Investment Income	762.8	762.8	729.28	698.55	711.53	1,106
Currency Exchange Gain (Loss)	-22.66	-22.66	-	-99.07	-51.36	-
Other Non Operating Income (Expenses)	-	-	-	-	37	0.08
EBT Excluding Unusual Items	12,166	11,870	9,101	8,066	7,666	6,266
Merger & Restructuring Charges	-	-	-1,633	-113.7	-200.84	-2.4
Gain (Loss) on Sale of Investments	696.5	696.5	487.76	307.79	5.92	-
Gain (Loss) on Sale of Assets	-15.13	-15.13	8.89	0.28	3.24	-0.59
Asset Writedown	-	-	-	-	2.61	-2,090
Other Unusual Items	46.92	46.92	196.87	104.02	314	366.44
Pretax Income	12,895	12,599	8,162	8,364	7,790	4,540
Income Tax Expense	3,392	3,323	2,262	2,288	3,983	1,667
Earnings From Continuing Operations	9,503	9,276	5,900	6,076	3,808	2,873
Earnings From Discontinued Operations	-	-	-	30.45	13,140	708.78
Net Income	9,503	9,276	5,900	6,107	16,947	3,581
Net Income to Common	9,503	9,276	5,900	6,107	16,947	3,581
Net Income Growth	48.47%	57.23%	-3.39%	-63.97%	373.19%	284.26%
Shares Outstanding (Basic)	169	169	169	169	169	169
Shares Outstanding (Diluted)	169	169	169	169	169	169
EPS (Basic)	56.10	54.76	34.83	36.05	100.04	21.14
EPS (Diluted)	56.10	54.76	34.83	36.05	100.04	21.14
EPS Growth	48.50%	57.23%	-3.39%	-63.97%	373.19%	284.26%
Free Cash Flow	-	12,669	5,508	4,402	7,761	5,337
Free Cash Flow Per Share	-	74.78	32.51	25.98	45.81	31.50
Dividend Per Share	-	42.000	32.000	32.000	30.000	30.000
Dividend Growth	-	31.25%	-	6.67%	-	50.00%
Gross Margin	62.48%	62.29%	60.76%	59.89%	57.96%	56.17%
Operating Margin	30.52%	29.72%	24.29%	23.02%	21.32%	17.76%
Profit Margin	25.36%	24.74%	17.08%	18.78%	51.70%	12.24%
Free Cash Flow Margin	-	33.79%	15.95%	13.54%	23.68%	18.24%
EBITDA	11,815	11,527	8,805	7,884	7,428	5,733
EBITDA Margin	31.53%	30.75%	25.50%	24.25%	22.66%	19.60%
D&A For EBITDA	375.63	383.57	415.36	399.67	439.6	537.22
EBIT	11,440	11,143	8,390	7,484	6,988	5,196
EBIT Margin	30.52%	29.72%	24.29%	23.02%	21.32%	17.76%
Effective Tax Rate	26.30%	26.38%	27.72%	27.35%	51.12%	36.72%
Revenue as Reported	38,937	38,951	35,763	33,524	33,538	30,362
Advertising Expenses	-	1,202	1,094	1,091	1,277	673.72

Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.